BACKGROUND: Insulin resistance is associated with @entity731 , but its mechanism is unknown. It has been reported that @entity3241 deficient ( @entity3241 -/-) @entity19 showed insulin resistance without @entity164 2 @entity6 , whereas the @entity3238 deficient ( @entity3238 -/-) @entity19 showed insulin resistance with @entity164 2 @entity6 . METHODS AND RESULTS: We investigated @entity8233 formation in the @entity3241 -/- and @entity3238 -/- @entity19 at 8 and 20 weeks. The @entity3238 -/- @entity19 showed much greater @entity8233 formation than the @entity3241 -/- and wild- @entity164 @entity19 at 8 weeks. At 20 weeks, the @entity3238 -/- @entity19 had greater @entity8233 formation than the @entity3241 -/- @entity19 , which showed more enhanced @entity8233 formation than the wild- @entity164 @entity19 . The @entity3241 -/- and @entity3238 -/- @entity19 had @entity2299 , @entity101 , and insulin resistance. The @entity3238 -/- @entity19 had more @entity209 than the @entity3241 -/- @entity19 at 8 and 20 weeks. @entity3238 expression was detected, but @entity3241 expression was not detected in the vessels. CONCLUSIONS: The @entity8233 formation in the @entity3241 -/- and @entity3238 -/- @entity19 appears to be related to abnormalities induced by the altered metabolic milieu in insulin-resistant states. Moreover, because @entity8233 formation was much greater in the @entity3238 -/- @entity19 than in the @entity3241 -/- @entity19 at 8 and 20 weeks, it is suggested that a lack of @entity3238 renders the vasculature more susceptible to injury in the abnormal metabolic milieu, and @entity3238 may have a protective effect on @entity8233 formation. We conclude that @entity3238 is protective and retards the development of @entity8233 formation in insulin-resistant states.

Lack of XXXX causes progressive @entity8233 .

@entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity2299 :: ('MESH:D050171', 'Disease') :: ['dyslipidemia'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity8233 :: ('MESH:D058426', 'Disease') :: ['neointima'] @entity3238 :: ('384783(Tax:10090)', 'Gene') :: ['IRS-2'] @entity164 :: ('MESH:D017827', 'Disease') :: ['type'] @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic abnormalities'] @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerosis'] @entity3241 :: ('16367(Tax:10090)', 'Gene') :: ['insulin receptor substrate (IRS)-1', 'IRS-1']
@entity3238 :: (384783(Tax:10090),Gene) :: ['insulin receptor substrate-2']
